In addition to the above-mentioned adverse effects of anti-VEGF treatment, pre-clinical and clinical reports suggest that cancer cells may develop resistance to anti-angiogenic therapy by different mechanisms that include (1) switch to a pro-migratory phenotype, (2) up-regulation of other pro-angiogenic molecules [151] and (3) the increased recruitment of myeloid cells that support tumor growth (reviewed in [7, 66, 129]). Here, VEGFA is linked to neoplasm.